Cargando…
Correction: Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
Autores principales: | Amano, Shogo, Kaino, Seiji, Shinoda, Shuhei, Harima, Hirofumi, Matsumoto, Toshihiko, Fujisawa, Koichi, Takami, Taro, Yamamoto, Naoki, Yamasaki, Takahiro, Sakaida, Isao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288778/ https://www.ncbi.nlm.nih.gov/pubmed/37353751 http://dx.doi.org/10.1186/s12885-023-11091-y |
Ejemplares similares
-
Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
por: Amano, Shogo, et al.
Publicado: (2020) -
Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo
por: Shinoda, Shuhei, et al.
Publicado: (2018) -
Deferasirox, a novel oral iron chelator, shows antiproliferative activity against pancreatic cancer in vitro and in vivo
por: Harima, Hirofumi, et al.
Publicado: (2016) -
Deferasirox, an oral iron chelator, prevents hepatocarcinogenesis and adverse effects of sorafenib
por: Yamamoto, Naoki, et al.
Publicado: (2016) -
Effects of an oral iron chelator, deferasirox, on advanced hepatocellular carcinoma
por: Saeki, Issei, et al.
Publicado: (2016)